Chemotherapeutics of visceral leishmaniasis: present and future developments

Leishmaniasis vaccines: past, present and future.

No vaccine exists against any form of leishmaniasis. Because recovery from infection is usually accompanied by a strong immunity and because it is possible to protect experimental animals against live challenge, hope for the development of a vaccine for humans has been high. However, leishmaniasis is a disease of the poor and the market for a vaccine is very limited. Until a few years ago, with...

Simultaneous Multithreading: Present Developments and Future Directions

Developments in Diagnosis of Visceral Leishmaniasis in the Elimination Era

Visceral leishmaniasis (VL) is the most devastating parasitic infection worldwide causing high morbidity and mortality. Clinical presentation of VL ranges from asymptomatic or subclinical infection to severe and complicated symptomatic disease. A major challenge in the clinical management of VL is the weakness of health systems in disease endemic regions. People affected by VL mostly present to...

Mizaj past, present and future

Temperament (Mizaj), as an individual factor, has great importance in traditional medicine and its use in diagnosis and treatment of diseases, as well as the individual lifestyle is very common. Since medicine moves toward Personalized Medicine, the root of individual differences will find its position in different aspects of medicine in early future. In traditional medicine, temperament is ...

Tuberculosis: Past, Present and Future

  Background Tuberculosis (TB) is the second-most common cause of death from infectious disease (after those due to HIV/AIDS). Roughly one-third of the world's population has been infected with M. tuberculosis, with new infections occurring in about 1% of the population each year. People with active TB can infect 10-15 other people through close contact over the course of a year. Materials and ...